PAI Pharmaceutical Expands with Acquisition of Teligent Assets
PAI Acquires Teligent’s U.S. Marketing Authorizations
Pharmaceutical Associates, Inc. (PAI) has acquired all the generic and branded U.S. marketing authorizations from Teligent Inc. (Teligent) for an undisclosed sum. This acquisition marks PAI's entry into sterile injectable and topical products.
Strategic Expansion into Sterile Injectables and Topical Products
The acquisition includes a portfolio of over 60 generic and branded applications, with around 50 approved applications and a pipeline of more than 15 additional filed products. PAI plans to commercialize select products from the portfolio, focusing on key U.S. market opportunities.
Comments from PAI Leadership
The Chief Commercial Officer of PAI stated, "This acquisition broadens our portfolio, specifically in sterile injectable products, and provides PAI with a platform to continue delivering value to our customers."
PAI's Chief Operating Officer added, "This is an exciting time for PAI. We are confident in our ability to launch the products acquired from Teligent, and we will continue to expand our portfolio through a combination of internal R&D and smart business development deals like this one."
Teligent’s Chapter 11 Filing and Asset Sale
In October 2021, Teligent filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code. As part of this process, Teligent initiated a sale of its core assets, leading to PAI’s agreement to acquire Teligent’s U.S. filings.
No comments:
Post a Comment